Lidia Rita Corsini

1.4k total citations
41 papers, 892 citations indexed

About

Lidia Rita Corsini is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Lidia Rita Corsini has authored 41 papers receiving a total of 892 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 15 papers in Molecular Biology and 13 papers in Cancer Research. Recurrent topics in Lidia Rita Corsini's work include Cancer Immunotherapy and Biomarkers (11 papers), BRCA gene mutations in cancer (10 papers) and Genetic factors in colorectal cancer (6 papers). Lidia Rita Corsini is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), BRCA gene mutations in cancer (10 papers) and Genetic factors in colorectal cancer (6 papers). Lidia Rita Corsini collaborates with scholars based in Italy, France and United States. Lidia Rita Corsini's co-authors include Daniele Fanale, Viviana Bazan, Antonio Russo, Valeria Amodeo, Giuseppe Bronte, Chiara Brando, Giuseppe Cicero, Lorena Incorvaia, Giuseppe Badalamenti and Stefania Rizzo and has published in prestigious journals such as Journal of Clinical Oncology, Oncogene and Annals of Oncology.

In The Last Decade

Lidia Rita Corsini

33 papers receiving 874 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lidia Rita Corsini Italy 19 430 381 323 180 164 41 892
Thomas P. Slavin United States 16 387 0.9× 255 0.7× 404 1.3× 262 1.5× 166 1.0× 44 917
Sarah M. Nielsen United States 16 255 0.6× 273 0.7× 340 1.1× 329 1.8× 147 0.9× 75 882
Samira Majjaj Belgium 12 498 1.2× 321 0.8× 449 1.4× 73 0.4× 145 0.9× 24 902
W. Li China 11 372 0.9× 684 1.8× 191 0.6× 158 0.9× 337 2.1× 47 981
Jeanie Wu Singapore 13 552 1.3× 218 0.6× 258 0.8× 81 0.5× 149 0.9× 14 904
Adriana López‐Doriga Spain 13 358 0.8× 456 1.2× 290 0.9× 158 0.9× 236 1.4× 24 938
Katherine C. Kurnit United States 15 327 0.8× 294 0.8× 231 0.7× 61 0.3× 146 0.9× 48 987
Susanne Malander Sweden 16 291 0.7× 497 1.3× 187 0.6× 257 1.4× 67 0.4× 44 1.0k
Joseph Vijai United States 16 332 0.8× 202 0.5× 298 0.9× 489 2.7× 128 0.8× 62 976

Countries citing papers authored by Lidia Rita Corsini

Since Specialization
Citations

This map shows the geographic impact of Lidia Rita Corsini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lidia Rita Corsini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lidia Rita Corsini more than expected).

Fields of papers citing papers by Lidia Rita Corsini

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lidia Rita Corsini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lidia Rita Corsini. The network helps show where Lidia Rita Corsini may publish in the future.

Co-authorship network of co-authors of Lidia Rita Corsini

This figure shows the co-authorship network connecting the top 25 collaborators of Lidia Rita Corsini. A scholar is included among the top collaborators of Lidia Rita Corsini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lidia Rita Corsini. Lidia Rita Corsini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Corsini, Lidia Rita, Chiara Brando, Alessandro Perez, et al.. (2024). 208P Role of plasma exosomes in crosstalk between immune system and hereditary ovarian cancer: Opportunity or challenge?. Annals of Oncology. 35. S300–S300. 1 indexed citations
2.
3.
Fanale, Daniele, Lidia Rita Corsini, Erika Pedone, et al.. (2023). Potential agnostic role of BRCA alterations in patients with several solid tumors: One for all, all for one?. Critical Reviews in Oncology/Hematology. 190. 104086–104086. 4 indexed citations
4.
Fanale, Daniele, Lidia Rita Corsini, Chiara Brando, et al.. (2022). Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?. Critical Reviews in Oncology/Hematology. 170. 103597–103597. 18 indexed citations
5.
Fanale, Daniele, Chiara Brando, Lidia Rita Corsini, et al.. (2022). MUTYH-associated tumor syndrome: The other face of MAP. Oncogene. 41(18). 2531–2539. 19 indexed citations
6.
Fanale, Daniele, Erika Pedone, Chiara Brando, et al.. (2022). Prognostic and Predictive Role of Tumor-Infiltrating Lymphocytes (TILs) in Ovarian Cancer. Cancers. 14(18). 4344–4344. 27 indexed citations
7.
8.
Incorvaia, Lorena, Lidia Rita Corsini, Chiara Brando, et al.. (2021). Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors. Critical Reviews in Oncology/Hematology. 163. 103390–103390. 5 indexed citations
9.
Fanale, Daniele, Chiara Brando, Alessia Fiorino, et al.. (2021). POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes. Oncogene. 40(40). 5893–5901. 45 indexed citations
10.
Brando, Chiara, Daniele Fanale, Lorena Incorvaia, et al.. (2021). 32P Can circulating immune checkpoints and KIT exon 11 mutations be prognostic factors in metastatic gastrointestinal stromal tumors?. Annals of Oncology. 32. S1386–S1386. 1 indexed citations
11.
Fanale, Daniele, Alessia Fiorino, Lorena Incorvaia, et al.. (2021). Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome. Frontiers in Oncology. 11. 682445–682445. 14 indexed citations
12.
Fanale, Daniele, Lorena Incorvaia, Clarissa Filorizzo, et al.. (2020). Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2. Cancers. 12(9). 2415–2415. 35 indexed citations
13.
14.
Fanale, Daniele, Lorena Incorvaia, Marco Bono, et al.. (2020). 247P Population-based testing for hereditary breast and ovarian cancer in a cohort of 1,346 patients from Southern Italy (Sicily): When historical background affects genetics. Annals of Oncology. 31. S338–S339. 1 indexed citations
15.
Incorvaia, Lorena, Daniele Fanale, Giuseppe Badalamenti, et al.. (2019). Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC). Advances in Therapy. 36(10). 2600–2617. 76 indexed citations
16.
Fiore, Riccardo Di, Daniele Fanale, Rosa Drago‐Ferrante, et al.. (2012). Genetic and molecular characterization of the human Osteosarcoma 3AB‐OS cancer stem cell line: A possible model for studying osteosarcoma origin and stemness. Journal of Cellular Physiology. 228(6). 1189–1201. 42 indexed citations
17.
Insalaco, Lavinia, Francesca Di Gaudio, Marianna Terrasi, et al.. (2012). Analysis of molecular mechanisms and anti‐tumoural effects of zoledronic acid in breast cancer cells. Journal of Cellular and Molecular Medicine. 16(9). 2186–2195. 23 indexed citations
18.
Fanale, Daniele, Valeria Amodeo, Lidia Rita Corsini, et al.. (2011). Breast cancer genome-wide association studies: there is strength in numbers. Oncogene. 31(17). 2121–2128. 89 indexed citations
19.
Calò, Valentina, Laura La Paglia, Lidia Rita Corsini, et al.. (2010). 79 VUS VARIANTS IN BRCA GENES OF HEREDITARY BREAST/OVARIAN CANCER. Cancer Treatment Reviews. 36. S118–S119. 1 indexed citations
20.
Rizzo, Sérgio, Giuseppe Bronte, Daniele Fanale, et al.. (2010). Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?. Cancer Treatment Reviews. 36. S56–S61. 75 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas P. Slavin Breakdown of academic impact, for papers by Sarah M. Nielsen Breakdown of academic impact, for papers by Samira Majjaj Breakdown of academic impact, for papers by W. Li Breakdown of academic impact, for papers by Jeanie Wu Breakdown of academic impact, for papers by Adriana López‐Doriga Breakdown of academic impact, for papers by Katherine C. Kurnit Breakdown of academic impact, for papers by Susanne Malander Breakdown of academic impact, for papers by Joseph Vijai
Rankless by CCL
2026